ATE422671T1 - Verfahren zur diagnose von morbus alzheimer - Google Patents

Verfahren zur diagnose von morbus alzheimer

Info

Publication number
ATE422671T1
ATE422671T1 AT03771762T AT03771762T ATE422671T1 AT E422671 T1 ATE422671 T1 AT E422671T1 AT 03771762 T AT03771762 T AT 03771762T AT 03771762 T AT03771762 T AT 03771762T AT E422671 T1 ATE422671 T1 AT E422671T1
Authority
AT
Austria
Prior art keywords
disease
diagnosing alzheimer
subject
methods
present
Prior art date
Application number
AT03771762T
Other languages
English (en)
Inventor
Yadong Huang
Original Assignee
David Gladstone Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Gladstone Inst filed Critical David Gladstone Inst
Application granted granted Critical
Publication of ATE422671T1 publication Critical patent/ATE422671T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
AT03771762T 2002-07-30 2003-07-24 Verfahren zur diagnose von morbus alzheimer ATE422671T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40001602P 2002-07-30 2002-07-30

Publications (1)

Publication Number Publication Date
ATE422671T1 true ATE422671T1 (de) 2009-02-15

Family

ID=31188657

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03771762T ATE422671T1 (de) 2002-07-30 2003-07-24 Verfahren zur diagnose von morbus alzheimer

Country Status (6)

Country Link
US (1) US7682795B2 (de)
EP (1) EP1543331B1 (de)
AT (1) ATE422671T1 (de)
AU (1) AU2003259222A1 (de)
DE (1) DE60326153D1 (de)
WO (1) WO2004011943A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
KR20060120161A (ko) * 2003-11-28 2006-11-24 아스트라제네카 아베 항체
WO2006110621A2 (en) * 2005-04-11 2006-10-19 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20090136456A1 (en) * 2006-12-22 2009-05-28 Yadong Huang Methods of treating neurodegenerative disorders
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009062152A1 (en) * 2007-11-09 2009-05-14 Washington University In St. Louis Methods for measuring the metabolism of cns derived biomolecules in vivo
US9102717B2 (en) * 2010-03-01 2015-08-11 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
US9488666B2 (en) 2010-08-24 2016-11-08 Helena Laboratories Corporation Assay for determination of levels of lipoprotein particles in bodily fluids
WO2012109280A2 (en) * 2011-02-07 2012-08-16 Neotope Biosciences Limited Apoe immunotherapy
KR102502356B1 (ko) 2014-09-30 2023-02-21 워싱턴 유니버시티 타우 (tau) 활동 계측
US10654917B2 (en) * 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
EP4685158A1 (de) * 2024-07-22 2026-01-28 Technische Universität München Fibrilläres apolipoprotein e (apoe) zur verwendung in einem verfahren zur behandlung und/oder prävention einer neurodegenerativen erkrankung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US6287793B1 (en) 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
CA2086165A1 (en) 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
WO1994009371A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
EP0625212B1 (de) * 1992-10-13 2004-03-24 Duke University VERFAHREN ZUM nachweis der Alzheimer Krankheit
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
US5849600A (en) 1993-11-10 1998-12-15 The Mclean Hospital Corporation Diagnostic assays for Alzheimer's disease
FR2716894B1 (fr) 1994-03-07 1996-05-24 Pasteur Institut Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic.
US5976798A (en) 1994-03-30 1999-11-02 Mitokor Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid
US5972634A (en) 1994-10-19 1999-10-26 The General Hospital Corporation Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5976817A (en) 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
WO1999045139A1 (en) 1998-03-05 1999-09-10 Board Of Regents, The University Of Texas System Diagnostic assay for late-onset alzheimer's disease
DE60134430D1 (de) * 2000-11-03 2008-07-24 David Gladstone Inst Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe
US6766817B2 (en) 2001-07-25 2004-07-27 Tubarc Technologies, Llc Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action

Also Published As

Publication number Publication date
AU2003259222A1 (en) 2004-02-16
EP1543331A1 (de) 2005-06-22
US7682795B2 (en) 2010-03-23
US20040157267A1 (en) 2004-08-12
EP1543331A4 (de) 2006-08-02
WO2004011943A1 (en) 2004-02-05
DE60326153D1 (de) 2009-03-26
EP1543331B1 (de) 2009-02-11

Similar Documents

Publication Publication Date Title
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
ATE386942T1 (de) Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
ATE283485T1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
ATE438737T1 (de) Verfahren für den nachweis von erkrankungen
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
EP1351707A4 (de) Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
ATE350659T1 (de) Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
DE60333195D1 (de) Verfahren zur diagnose des myokardinfarktrisikos
DE602004029061D1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
DE50007635D1 (de) Verfahren zur diagnose von sjögren-syndrom
ATE406579T1 (de) Verfahren zur diagnose von tumoren
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
ATE302416T1 (de) Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit
ATE211825T1 (de) Verfahren zur feststellung einer allergie
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
DE602004022995D1 (de) Verfahren zur diagnose der immunität wiederkehrendren zur behandlung und überwachung
ATE423321T1 (de) Verfahren zur detektion von prpsc unter verwendung von gruppe ii aminoglykosid antibiotika

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties